Phage display broadly identifies inhibitor-reactive regions in von Willebrand factor

J Thromb Haemost. 2021 Nov;19(11):2702-2709. doi: 10.1111/jth.15460. Epub 2021 Jul 28.

Abstract

Background: Correction of von Willebrand factor (VWF) deficiency with replacement products containing VWF can lead to the development of anti-VWF alloantibodies (i.e., VWF inhibitors) in patients with severe von Willebrand disease (VWD).

Objective: Locate inhibitor-reactive regions within VWF using phage display.

Methods: We screened a phage library displaying random, overlapping fragments covering the full-length VWF protein sequence for binding to a commercial anti-VWF antibody or to immunoglobulins from three type 3 VWD patients who developed VWF inhibitors in response to treatment with plasma-derived VWF. Immunoreactive phage clones were identified and quantified by next-generation DNA sequencing (NGS).

Results: Next-generation DNA sequencing markedly increased the number of phages analyzed for locating immunoreactive regions within VWF following a single round of selection and identified regions not recognized in previous reports using standard phage display methods. Extending this approach to characterize VWF inhibitors from three type 3 VWD patients (including two siblings homozygous for the same VWF gene deletion) revealed patterns of immunoreactivity distinct from the commercial antibody and between unrelated patients, though with notable areas of overlap. Alloantibody reactivity against the VWF propeptide is consistent with incomplete removal of the propeptide from plasma-derived VWF replacement products.

Conclusion: These results demonstrate the utility of phage display and NGS to characterize diverse anti-VWF antibody reactivities.

Keywords: anti-VWF alloantibodies; next-generation DNA sequencing; phage display; von Willebrand disease; von Willebrand factor.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bacteriophages*
  • Homozygote
  • Humans
  • von Willebrand Disease, Type 3*
  • von Willebrand Diseases* / diagnosis
  • von Willebrand Diseases* / drug therapy
  • von Willebrand Diseases* / genetics
  • von Willebrand Factor / genetics

Substances

  • von Willebrand Factor